RxDoctor Payments Data

Laura Allen

Family · Lawndale, NCNPI 1316370471

Payments from drug & device makers

$793in general payments, 2019–2025

Across 20 payments — averaging $39.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$289
  • Axonics, Inc.$115
  • Exact Sciences$98
  • Sun Pharmaceutical Industries Inc.$76
  • AbbVie$55
  • Pfizer$50
  • plus $110 from 5 others

What the payments were for

  • Food & beverage$76897%
  • Education$253%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$793 in reported general payments places this provider in the 65th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$69,699
Medicare patients
173
Services billed
1,028

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban112$122,898
OzempicSemaglutide93$95,405
MounjaroTirzepatide36$57,873
JardianceEmpagliflozin60$53,691
Repatha SureclickEvolocumab63$47,963
Tresiba Flextouch U-100Insulin Degludec69$34,321
FarxigaDapagliflozin Propanediol35$32,310
LinzessLinaclotide29$28,139
RybelsusSemaglutide20$28,009
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$27,223
XareltoRivaroxaban36$26,284
TradjentaLinagliptin28$24,256
MyrbetriqMirabegron39$24,052
VascepaIcosapent Ethyl42$18,731
TrulicityDulaglutide19$18,445

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$50$127,972130 claims
Novo NordiskOzempic, Rybelsus$16$123,415113 claims
Boehringer IngelheimJardiance, Tradjenta$16$77,94788 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$289$49,90474 claims
AbbVieLinzess, Synthroid$55$37,683176 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,522 family providers in North Carolina.

Other family in Lawndale

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →